Barclays raised the firm’s price target on Encompass Health (EHC) to $129 from $118 and keeps an Overweight rating on the shares following the Q1 report. The firm continues to view Encompass as one of the most defensive stocks in its coverage that is largely insulated from current policy risk.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health: Strong Financial Performance and Resilient Growth Justify Buy Rating
- Encompass Health Appoints New COO Patrick W. Tuer
- Encompass Health names Patrick Tuer as COO, effective immediately
- Encompass Health reports Q1 adjusted EPS $1.37, consensus $1.19
- Encompass Health raises FY25 adjusted EPS view to $4.85-$5.10 from $4.67-$4.96